Результаты поиска

Role of phytoconstituents in the management of COVID-19.

BackgroundCOVID-19, a severe global pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has emerged as one of the most threatening transmissible disease. As a great threat to global public health, the development of treatment options has become vital, and a rush to find a cure has mobilized researchers globally from all areas.Scope and approachThis review focuses on deciphering the potential of different secondary metabolites from medicinal plants as therapeutic options either as inhibitors of therapeutic targets of SARS-CoV-2 or as blockers of viral particles entry

Совпадение в полном тексте источника
… clinical trials [ 13 ] BLD-2660 Antiviral Targets IL6 Under phase 2 of clinical trials [ 13 ] Sildenafil citrate Phospho-diesterase inhibitor Dilates blood vessles Under phase 3 of clinical trials [ 13 ] Losartan Angiotensin II receptor antagonist Targets ACE2 Under phase 1 of clinical trials [ 13 ] Telmisartan … BLD-2660 | Antiviral | Targets IL6 | Under phase 2 of clinical trials | [ 13 ] Sildenafil citrate | Phospho-diesterase inhibitor | Dilates blood vessles | Under phase 3 of clinical trials | [ 13 ] Losartan | Angiotensin II receptor antagonist | Targets ACE2 | Under phase 1 of clinical trials | [ 13 ] Telmisartan …

Evidence for reciprocal network interactions between injured hearts and cancer.

Heart failure (HF) and cancer are responsible for 50% of all deaths in middle-aged people. These diseases are tightly linked, which is supported by recent epidemiological studies and case control studies, demonstrating that HF patients have a higher risk to develop cancer such as lung and breast cancer. For HF patients, a one-size-fits-all clinical management strategy is not effective and patient management represents a major economical and clinical burden. Anti-cancer treatments-mediated cardiotoxicity, leading to HF have been extensively studied. However, recent studies showed that even befo

Совпадение в полном тексте источника
… ARB use in patients with type 2 diabetes demonstrated a negative association for losartan (ARB), but a positive association for candesartan and telmisartan with the overall occurrence of cancer ( 84 ). …

New strategies and perspectives on managing IgA nephropathy.

IgA nephropathy is an inflammatory renal disease characterised by the deposition of IgA in the glomerular mesangium and is the most commonly reported primary glomerulonephritis worldwide. Thirty to forty percent of patients with the disease develop progressive renal function decline, requiring renal replacement therapy within two decades of diagnosis. Despite this, accurate individual risk stratification at diagnosis and predicting treatment response remains a challenge. Furthermore, there are currently no disease specific treatments currently licensed to treat the condition due to long standi

Совпадение в полном тексте источника
… Mann JFE Schmieder RE McQueen M Dyal L Schumacher H Pogue J Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial Lancet 2008 372 9638 547 553 18707986 10.1016/S0140-6736(08)61236-2 47. …

Epigenetic modification in diabetic kidney disease.

Diabetic kidney disease (DKD) is a common microangiopathy in diabetic patients and the main cause of death in diabetic patients. The main manifestations of DKD are proteinuria and decreased renal filtration capacity. The glomerular filtration rate and urinary albumin level are two of the most important hallmarks of the progression of DKD. The classical treatment of DKD is controlling blood glucose and blood pressure. However, the commonly used clinical therapeutic strategies and the existing biomarkers only partially slow the progression of DKD and roughly predict disease progression. Therefor

Совпадение в полном тексте источника
… inhibitor | Approved medication | Blood pressure↓ Weight↓ Glomerular pressure↓ GFR↑ Albuminuria↓ | ( 226 – 229 ) Sitagliptin Linagliptin | DPP-4 inhibitor | Approved medication | Blood glucose↓ Oxidative stress↓ Inflammation↓ Glomerular injury↓ Albuminuria↓ | ( 172 , 230 – 234 ) Captopril Losartan Telmisartan … Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care (2007) 30(6):1577–8. doi: 10.2337/dc06-1998 223. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. …

Repurposing drugs for highly prevalent diseases: pentoxifylline, an old drug and a new opportunity for diabetic kidney disease.

Diabetic kidney disease is one of the most frequent complications in patients with diabetes and constitutes a major cause of end-stage kidney disease. The prevalence of diabetic kidney disease continues to increase as a result of the growing epidemic of diabetes and obesity. Therefore, there is mounting urgency to design and optimize novel strategies and drugs that delay the progression of this pathology and contain this trend. The new approaches should go beyond the current therapy focussed on the control of traditional risk factors such as hyperglycaemia and hypertension. In this scenario, d

Совпадение в полном тексте источника
… Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (The ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547–553 23. Esteras R, Perez-Gomez MV, Rodriguez-Osorio Let al. …

Cardio-oncology: conflicting priorities of anticancer treatment and cardiovascular outcome.

BackgroundThis article about the emerging field of cardio-oncology highlights typical side effects of oncological therapies in the cardiovascular system, cardiovascular complications of malignancies itself, and potential preventive or therapeutic modalities.MethodsWe performed a selective literature search in PubMed until September 2016.ResultsCardiovascular events in cancer patients can be frequently attributed to oncological therapies or to the underlying malignancy itself. Furthermore, many patients with cancer have pre-existing cardiovascular diseases that can be aggravated by the malignan

Совпадение в полном тексте источника
… Dessi M Madeddu C Piras A Cadeddu C Antoni G Mercuro G Mantovani G Long-term, up to 18 months, protective effects of the angiotensin II receptor blocker telmisartan on Epirubin-induced inflammation and oxidative stress assessed by serial strain rate Springerplus 2013 2 1 198 10.1186/2193-1801-2-198 23741643 …

Nuclear receptors in health and disease: signaling pathways, biological functions and pharmaceutical interventions.

Nuclear receptors (NRs) are a large family of ligand-dependent transcription factors that regulate the expression of a wide range of target genes in response to endogenous and exogenous ligands, including steroid hormones, thyroid hormone, vitamin D, retinoic acid, fatty acids, and oxidative steroids. Upon ligand binding, nuclear receptors form dimer complexes with transcriptional cofactors, which interact with specific DNA sequences in the promoter or enhancer regions of target genes to modulate gene expression. This process plays a crucial role in many physiological processes such as reprodu

Совпадение в полном тексте источника
… outcomes were also combined for the study) Anaplastic Thyroid Cancer CS-7017; Paclitaxel PHASE1; PHASE2 NCT00193648 COMPLETED (No Results Posted) Focal Glomerulosclerosis Rosiglitazone (Avandia); Adalimumab (Humira) PHASE1 NCT00407862 COMPLETED (No Results Posted) Hypertension; Impaired Glucose Tolerance Telmisartan … conclusion) Opioid Abuse Pioglitazone PHASE2 NCT01019356 COMPLETED (No Results Posted) Polycystic Ovary Syndrome Rosiglitazone; Acarbose NA NCT02696577 COMPLETED (No Results Posted) Intrauterine Growth Restriction Low dose aspirin; Omega 3 PHASE2 NCT00452192 COMPLETED (No Results Posted) Metabolic Syndrome Telmisartan …

Alpha-lipoic acid as a trigger of insulin autoimmune syndrome: Current evidence, a case-based approach, diagnostic pitfalls, and practical management.

Insulin autoimmune syndrome (IAS), also known as Hirata disease, is a rare immune-mediated cause of endogenous hyperinsulinemic hypoglycemia characterized by circulating insulin autoantibodies (IAAs). It typically develops in individuals without prior exposure to exogenous insulin. Although IAS has been associated with viral infections and, less commonly, with autoimmune and hematologic disorders, medications and dietary supplements are considered the most frequent precipitating factors. Sulfhydryl-containing compounds are the most commonly implicated triggers. Methimazole represents the class

Совпадение в полном тексте источника
… glucose: 20 mg during OGTT ✔ C-peptide: 23.02 ng/ml ✔ Serum insulin >1000 μIU/mL ✔ IAAs: 98 IU/mL | ✔ ALA discontinuation ✔ MNT with acarbose 25 mg 3 times/daily with meals for 6 months ✔ Clinical remission Mudagall, 2025 [ 76 ] | ✔ A 64-year-old male ✔ History of hypertension under treatment with telmisartan …

Lifestyle and Pharmacological Interventions to Prevent Anthracycline-Related Cardiotoxicity in Cancer Patients.

Anthracyclines remain a cornerstone of cancer therapy but are associated with a significant risk of cardiotoxicity, which can lead to overt heart failure. The risk is modulated by cumulative dose, pre-existing cardiovascular disease, and patient-specific factors. As cancer survival improves, the long-term cardiovascular consequences of anthracycline exposure have become a growing concern, underscoring the need for effective preventive strategies. This narrative review examines lifestyle and pharmacological interventions aimed at mitigating anthracycline-induced cardiotoxicity. Evidence suggest

Совпадение в полном тексте источника
… Long-term, up to 18 months, protective effects of the angiotensin II receptor blocker telmisartan on Epirubin-induced inflammation and oxidative stress assessed by serial strain rate Springerplus 2013 2 198 10.1186/2193-1801-2-198 23741643 PMC3664751 100. Lother A. Bergemann S. Kowalski J. Huck M. …

The prince and the pauper. A tale of anticancer targeted agents.

Cancer rates are set to increase at an alarming rate, from 10 million new cases globally in 2000 to 15 million in 2020. Regarding the pharmacological treatment of cancer, we currently are in the interphase of two treatment eras. The so-called pregenomic therapy which names the traditional cancer drugs, mainly cytotoxic drug types, and post-genomic era-type drugs referring to rationally-based designed. Although there are successful examples of this newer drug discovery approach, most target-specific agents only provide small gains in symptom control and/or survival, whereas others have consiste

Совпадение в полном тексте источника
… Similarly, there are a number of orally available angiotensin II receptor blockers such as candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan , and valsartan . These agents may be safely begun in persons < 60 years of age with initial serum creatinine of ≤ 3 mg/dL. … Some angiotensin type 1 receptor blockers, such as telmisartan, candesartan, irbesartan, and losartan, are peroxisome proliferator-activated receptor-gamma pathway agonists; hence, this pathway may also explain some antitumor effects of these agents [ 110 ]. …

Primed for global coronavirus pandemic: Emerging research and clinical outcome.

The global effort to combat and contain the coronavirus disease 2019 (COVID-19) caused by the recently discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now proceeding on a war footing. The world was slow to react to the developing crisis, but once the contours of the impending calamity became evident, the different state and non-state actors have raced to put their act together. The COVID-19 pandemic has blatantly exposed the shortcomings of our healthcare system and the limitations of medical science, despite considerable advances in recent years. To effectively tack

Совпадение в полном тексте источника
… ClinicalTrials.gov ) | Selective serotonin reuptake inhibitor (SSRI) 54 | Ibuprofen (58) | King’s College London, UK | Phase-IV, NCT04334629 ( ClinicalTrials.gov ) | NSAID 55 | Valsartan ( 59 ) | Radboud University, Netherlands | Phase-IV, NCT04335786 ( ClinicalTrials.gov ) | Angiotensin II inhibitor 56 | Telmisartan …

Repurposing anticancer drugs for the management of COVID-19.

Since its outbreak in the last December, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has rapidly spread worldwide at a pandemic proportion and thus is regarded as a global public health emergency. The existing therapeutic options for COVID-19 beyond the intensive supportive care are limited, with an undefined or modest efficacy reported so far. Drug repurposing represents an enthusiastic mechanism to use approved drugs outside the scope of their original indication and accelerate the discovery of new therapeutic options. With the emergence of COVID-19, drug repurposing has been la

Совпадение в полном тексте источника
… A total of 1057 symptomatic COVID-19 patients will be randomly allocated to receive imatinib, or telmisartan, or favipiravir, or hydroxychloroquine as compared to a control group with the objective to reduce the risk of hospitalisation or death in elderly patients. …

Left Ventricular Hypertrophy: Etiology-Based Therapeutic Options.

Determining the etiologies of left ventricular hypertrophy (LVH) can be challenging due to the similarities of the different manifestations in clinical presentation and morphological features. Depending on the underlying cause, not only left ventricular mass but also left ventricular cavity size, or both, may increase. Patients with LVH remain asymptomatic for a few years, but disease progression will lead to the development of systolic or diastolic dysfunction and end-stage heart failure. As hypertrophied cardiac muscle disrupts normal conduction, LVH predisposes to arrhythmias. Distinguishin

Совпадение в полном тексте источника
… Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass: a multicenter, randomized, longitudinal study. Am J Hypertens. 2005;18(12):1563–1569. doi: 10.1016/j.amjhyper.2005.06.011. 25. …

Drug repurposing: A novel strategy to target cancer stem cells and therapeutic resistance.

Chemotherapy is an effortless and frequently used approach in cancer therapy. However, in most cases, it can only prolong life expectancy and does not guarantee a complete cure. Furthermore, chemotherapy is associated with severe adverse effects, one of the major complications of effective cancer therapy. In addition, newly published research outputs show that cancer stem cells are involved in cancer disease progression, drug resistance, metastasis, and recurrence and that they are functional in the trans-differentiation capacity of cancer stem cells to cancer cells in response to treatments.

Совпадение в полном тексте источника
… self-renewal ability, and population of CSCs of colorectal cancer. 183 Trifluoperazine, an anti-psychotic and antiemetic agent, inhibits the spheroid formation ability of CSCs and suppresses CD44/CD133 markers' expression in lung CSCs by inhibiting Wnt/β-catenin signal transduction. 184 Actinomycin D and telmisartan …

Insights into Endothelial Progenitor Cells: Origin, Classification, Potentials, and Prospects.

With the discovery of endothelial progenitor cells (EPCs) in the late 1990s, a paradigm shift in the concept of neoangiogenesis occurred. The identification of circulating EPCs in peripheral blood marked the beginning of a new era with enormous potential in the rapidly transforming regenerative field. Overwhelmed with the revelation, researchers across the globe focused on isolating, defining, and interpreting the role of EPCs in various physiological and pathological conditions. Consequently, controversies emerged regarding the isolation techniques and classification of EPCs. Nevertheless, th

Cancer stem cells in personalized therapy: mechanisms, microenvironment crosstalk, and therapeutic vulnerabilities.

Cancer stem cells (CSCs) drive tumor progression, therapy resistance, and metastasis through unique membrane biology, glycosylation patterns, and metabolic adaptations. CSCs exhibit a distinct glycocalyx profile enriched in hyaluronan, heparan sulfate, and sialylated glycans, facilitating immune evasion, adhesion, and survival. Key signaling pathways-Wnt/β-catenin, Hedgehog, Notch, JAK/STAT, TGF/SMAD, and PI3K/AKT/mTOR-regulate CSC stemness and therapeutic resistance. Emerging biomarkers (CD44, CD133, ALDH1, EpCAM) and targeted therapies (CAR-T cells, miRNA modulation, lipid metabolism inhibit

Совпадение в полном тексте источника
… Actinomycin D and Telmisartan combination targets lung cancer stem cells through the wnt/beta catenin pathway. Sci. Rep. 9 (1), 18177. 10.1038/s41598-019-54266-z Gulaia V., Kumeiko V., Shved N., Cicinskas E., Rybtsov S., Ruzov A., et al. (2018). …

Drug repurposing approach to fight COVID-19.

Currently, there are no treatment options available for the deadly contagious disease, coronavirus disease 2019 (COVID-19). Drug repurposing is a process of identifying new uses for approved or investigational drugs and it is considered as a very effective strategy for drug discovery as it involves less time and cost to find a therapeutic agent in comparison to the de novo drug discovery process. The present review will focus on the repurposing efficacy of the currently used drugs against COVID-19 and their mechanisms of action, pharmacokinetics, dosing, safety, and their future perspective. R

Совпадение в полном тексте источника
… However, losartan should be started with a lower dose in hepatic impairment and telmisartan should be avoided in case of renal impairment and congestive heart failure/digoxin therapy [ 149 , 150 ]. …

Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses.

The world was unprepared for coronavirus disease 2019 (COVID-19) and remains ill-equipped for future pandemics. While unprecedented strides have been made developing vaccines and treatments for COVID-19, there remains a need for highly effective and widely available regimens for ambulatory use for novel coronaviruses and other viral pathogens. We posit that a priority is to develop pan-family drug cocktails to enhance potency, limit toxicity, and avoid drug resistance. We urge cocktail development for all viruses with pandemic potential both in the short term (<1 to 2 years) and longer term wi

Совпадение в полном тексте источника
… imino sugars, IQ-1S, ivermectin, ivosidenib, lapatinib, lenvatinib, linoleic acid, mefloquine, meprednisone, MU-UNMC-2, nelfinavir, nifedipine, nimodipine, nitazoxanide, omeprazole, omipalisib, pioglitazone, quinapril, raloxifene, reserpine, rifaximin, sangivamycin, selexipag, stenoparib, sulforaphane, telmisartan …

Chemotherapy-induced acute kidney injury: epidemiology, pathophysiology, and therapeutic approaches.

Despite significant advancements in oncology, conventional chemotherapy remains the primary treatment for diverse malignancies. Acute kidney injury (AKI) stands out as one of the most prevalent and severe adverse effects associated with these cytotoxic agents. While platinum compounds are well-known for their nephrotoxic potential, other drugs including antimetabolites, alkylating agents, and antitumor antibiotics are also associated. The onset of AKI poses substantial risks, including heightened morbidity and mortality rates, prolonged hospital stays, treatment interruptions, and the need for

Совпадение в полном тексте источника
… Telmisartan ameliorates cisplatin-induced nephrotoxicity by inhibiting MAPK mediated inflammation and apoptosis. Eur J Pharmacol. (2015) 748:54–60. doi: 10.1016/j.ejphar.2014.12.008 112. Francescato HDC, Costa RS, Junior FB, Coimbra TM. Effect of JNK inhibition on cisplatin-induced renal damage. …

Artificial Intelligence and Machine Learning Technology Driven Modern Drug Discovery and Development.

The discovery and advances of medicines may be considered as the ultimate relevant translational science effort that adds to human invulnerability and happiness. But advancing a fresh medication is a quite convoluted, costly, and protracted operation, normally costing USD ~2.6 billion and consuming a mean time span of 12 years. Methods to cut back expenditure and hasten new drug discovery have prompted an arduous and compelling brainstorming exercise in the pharmaceutical industry. The engagement of Artificial Intelligence (AI), including the deep-learning (DL) component in particular, has bee

Совпадение в полном тексте источника
… To cite an exemplar, this approach proposed that alendronate, chlorpropamide, and telmisartan could possess novel cyclooxygenase blocking actions. …